Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | integrin alpha-V |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6468H10008N1744O2006S40 |
Molar mass | 145579.81 g·mol−1 |
![]() ![]() |
Intetumumab is a human monoclonal antibody targeting integrins [1] that was being studied for the treatment of solid tumors. [2]
Intetumumab was developed by Centocor, Inc.
Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued. [3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | integrin alpha-V |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6468H10008N1744O2006S40 |
Molar mass | 145579.81 g·mol−1 |
![]() ![]() |
Intetumumab is a human monoclonal antibody targeting integrins [1] that was being studied for the treatment of solid tumors. [2]
Intetumumab was developed by Centocor, Inc.
Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued. [3]